Daniel George, MD
Urology · Durham, NCNPI 1124101381
Payments from drug & device makers
Across 683 payments — averaging $25,828 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$3.1M
- Novartis$2.5M
- Pfizer$2.3M
- Janssen Research & Development, LLC$2.1M
- E.r. Squibb & Sons, L.L.C.$1.8M
- AstraZeneca$1.5M
- plus $4.4M from 21 others
Across 66 payments — averaging $1513.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$72K
- Novartis$21K
- Astellas Pharma Global Development$4K
- Myovant Sciences Inc.$3K
- Novartis Pharma AG$812
What the payments were for
- Consulting fees$694,84269%
- Speaking & faculty fees$256,97526%
- Travel & lodging$42,8064%
- Food & beverage$6,6351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 76 | $3,067,877 |
| Novartis | 43 | $2,506,844 |
| Pfizer | 89 | $2,294,050 |
| Janssen Research & Development, LLC | 71 | $2,065,875 |
| E.r. Squibb & Sons, L.L.C. | 19 | $1,800,887 |
| AstraZeneca | 47 | $1,524,029 |
| Sanofi | 46 | $1,242,282 |
| Merck | 50 | $858,145 |
| Astrazeneca UK Limited | 42 | $830,633 |
| Bayer | 143 | $674,414 |
| Janssen Scientific Affairs, LLC | 5 | $382,014 |
| Amgen | 1 | $168,750 |
| Acerta Pharma LLC | 1 | $113,708 |
| Blue Earth Diagnostics | 3 | $29,451 |
| Astellas Pharma US Inc | 9 | $19,133 |
| Advanced Accelerator Applications | 6 | $14,228 |
| Eisai Inc. | 9 | $13,795 |
| Sumitomo Pharma America, Inc. | 3 | $7,967 |
| Myovant Sciences Inc. | 3 | $7,347 |
| Seagen Inc. | 4 | $6,342 |
| F. Hoffmann-la Roche AG | 1 | $6,066 |
| Astrazeneca AB | 3 | $3,060 |
| Janssen Global Services, LLC | 1 | $2,430 |
| Aadi Bioscience, Inc. | 1 | $1,000 |
| AVEO Pharmaceuticals, Inc. | 3 | $306 |
| Dendreon Pharmaceuticals LLC | 3 | $159 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,640,803 in reported general payments places this provider in the 95th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 51 | $1,201,813 |
| NubeqaDarolutamide | 65 | $812,745 |
| LenvimaLenvatinib Mesylate | 27 | $610,466 |
| FotivdaTivozanib Hcl | 17 | $442,659 |
| XtandiEnzalutamide | 34 | $438,262 |
| InlytaAxitinib | 19 | $373,930 |
| WeliregBelzutifan | 16 | $217,540 |
| OrgovyxRelugolix | 91 | $216,568 |
| Abiraterone Acetate | 53 | $71,078 |
| Everolimus | 18 | $36,147 |
| EliquisApixaban | 24 | $12,454 |
| Prochlorperazine Maleate | 29 | $430 |
| Dexamethasone | 15 | $408 |
| Tamsulosin Hcl | 16 | $323 |
| Prednisone | 77 | $309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $3,067,877 | $1,201,81351 claims |
| BayerNubeqa | $674,414 | $812,74565 claims |
| Eisai Inc.Lenvima | $13,795 | $610,46627 claims |
| Astellas Pharma US IncXtandi | $19,133 | $438,26234 claims |
| PfizerInlyta, Eliquis | $2,294,050 | $386,38443 claims |
| MerckWelireg | $858,145 | $217,54016 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $7,967 | $216,56891 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $382,014 | $71,07853 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 urology providers in North Carolina.
Other urology in Durham
- Thomas PolascikDurham$4.7M
- Judd MoulDurham$4.1M
- Glenn PremingerDurham$736K
- Michael LipkinDurham$513K
- Brant InmanDurham$441K
- Andrew PetersonDurham$297K
- Jay KimDurham$202K
- Kathleen McGinleyDurham$159K
- John WienerDurham$113K
- Cary RobertsonDurham$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.